Bruce Cree
Impact in
- Pathology and Forensic Medicine top 0.01%
- Multiple Sclerosis Research Studies
- Neurology top 1%
- Neuroinflammation and Neurodegeneration Mechanisms
- Autoimmune Neurological Disorders and Treatments
Papers in
-
- Multiple Sclerosis Research Studies 324
-
- Balance, Gait, and Falls Prevention 4
- Co-authors
- Stephen L. Hauser (59 shared papers)Jeffrey Marc Gelfand (27 shared papers)Scott S. Zamvil (16 shared papers)Sergio E. Baranzini (24 shared papers)Hans‐Peter Hartung (55 shared papers)Douglas S. Goodin (11 shared papers)Emmanuelle L. Waubant (9 shared papers)Collin M. Spencer (9 shared papers)
- Journals
- Neurology (95 papers)Multiple Sclerosis Journal (28 papers)Annals of Neurology (23 papers)Multiple Sclerosis and Related Disorders (22 papers)Neurology Neuroimmunology & Neuroinflammation (20 papers)
- Partner nations
- United StatesGermanySwitzerland
In The Last Decade
Bruce Cree
339 papers receiving 22.8k citations
Bruce Cree's Hit Papers
Peers
Comparison fields: 5 of 146
- Pathology and Forensic Medicine 16.4k
- Neurology 576
- Developmental Neuroscience 173
- Neurology 726
- Immunology 827
Countries citing papers authored by Bruce Cree
This map shows the geographic impact of Bruce Cree's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bruce Cree with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bruce Cree more than expected).
Fields of papers citing papers by Bruce Cree
This network shows the impact of papers produced by Bruce Cree. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bruce Cree. The network helps show where Bruce Cree may publish in the future.
Co-authors
The 25 scholars most cited alongside Bruce Cree, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 354 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis Hit paper breakdown → | 2011 | 2243 |
| 2 | Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis Hit paper breakdown → | 2013 | 1141 |
| 3 | Gut bacteria from multiple sclerosis patients modulate human T cells and exacerbate symptoms in mouse models Hit paper breakdown → | 2017 | 837 |
| 4 | Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study Hit paper breakdown → | 2018 | 747 |
| 5 | Treatment of Multiple Sclerosis: A Review Hit paper breakdown → | 2020 | 681 |
| 6 | Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial Hit paper breakdown → | 2019 | 587 |
| 7 | An open label study of the effects of rituximab in neuromyelitis optica Hit paper breakdown → | 2005 | 556 |
| 8 | Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis Hit paper breakdown → | 2018 | 471 |
| 9 | Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trial Hit paper breakdown → | 2017 | 454 |
| 10 | 2008 | 403 | |
| 11 | 2008 | 391 | |
| 12 | Silent progression in disease activity–free relapsing multiple sclerosis Hit paper breakdown → | 2019 | 383 |
| 13 | Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial Hit paper breakdown → | 2016 | 377 |
| 14 | Long‐term evolution of multiple sclerosis disability in the treatment era Hit paper breakdown → | 2016 | 354 |
| 15 | 2012 | 302 | |
| 16 | 2004 | 269 | |
| 17 | 2006 | 269 | |
| 18 | Dimethyl fumarate treatment induces adaptive and innate immune modulation independent of Nrf2 Hit paper breakdown → | 2016 | 264 |
| 19 | 2004 | 262 | |
| 20 | 2016 | 249 |
About Bruce Cree
Bruce Cree is a scholar working on Pathology and Forensic Medicine, Physical Therapy, Sports Therapy and Rehabilitation, Radiology, Nuclear Medicine and Imaging, Infectious Diseases and Molecular Biology, having authored 354 papers that have together received 23.4k indexed citations. Recurring topics across this work include Multiple Sclerosis Research Studies (324 papers), Gut microbiota and health (9 papers), Balance, Gait, and Falls Prevention (4 papers), Advanced MRI Techniques and Applications (4 papers), Physical Activity and Health (3 papers), Inflammatory Bowel Disease (3 papers), Hereditary Neurological Disorders (2 papers) and Genetic Neurodegenerative Diseases (2 papers). The work is most often cited by research in Pathology and Forensic Medicine (16.4k citations), Neurology (576 citations), Developmental Neuroscience (173 citations), Neurology (726 citations) and Immunology (827 citations). Bruce Cree has collaborated with scholars based in United States, Germany and Switzerland. Frequent co-authors include Stephen L. Hauser, Jeffrey Marc Gelfand, Scott S. Zamvil, Sergio E. Baranzini, Hans‐Peter Hartung, Douglas S. Goodin, Emmanuelle L. Waubant, Collin M. Spencer, Carolyn J. Bevan and Jorge R. Oksenberg. Their work appears in journals such as Neurology, Multiple Sclerosis Journal, Annals of Neurology, Multiple Sclerosis and Related Disorders and Neurology Neuroimmunology & Neuroinflammation.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.